| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | intracellularly calcium-gated chloride channel activity | 3.81e-04 | 20 | 29 | 2 | GO:0005229 | |
| GeneOntologyMolecularFunction | intracellularly calcium-gated channel activity | 3.81e-04 | 20 | 29 | 2 | GO:0141147 | |
| GeneOntologyMolecularFunction | phospholipid scramblase activity | 5.06e-04 | 23 | 29 | 2 | GO:0017128 | |
| GeneOntologyMolecularFunction | ligand-gated monoatomic anion channel activity | 2.39e-03 | 50 | 29 | 2 | GO:0099095 | |
| GeneOntologyMolecularFunction | intramembrane lipid transporter activity | 2.48e-03 | 51 | 29 | 2 | GO:0140303 | |
| Domain | - | 1.39e-05 | 4 | 29 | 2 | 3.90.1460.10 | |
| Domain | GTF2I | 1.39e-05 | 4 | 29 | 2 | IPR004212 | |
| Domain | GTF2I | 1.39e-05 | 4 | 29 | 2 | PS51139 | |
| Domain | GTF2I | 1.39e-05 | 4 | 29 | 2 | PF02946 | |
| Domain | Anoct_dimer | 4.87e-05 | 7 | 29 | 2 | PF16178 | |
| Domain | Anoct_dimer | 4.87e-05 | 7 | 29 | 2 | IPR032394 | |
| Domain | Anoctamin | 1.04e-04 | 10 | 29 | 2 | PF04547 | |
| Domain | Anoctamin | 1.04e-04 | 10 | 29 | 2 | IPR007632 | |
| Domain | RNaseH-like_dom | 5.12e-03 | 69 | 29 | 2 | IPR012337 | |
| Domain | Znf_C2H2-like | 7.04e-03 | 796 | 29 | 5 | IPR015880 | |
| Domain | ZnF_C2H2 | 7.49e-03 | 808 | 29 | 5 | SM00355 | |
| Pathway | REACTOME_INDUCTION_OF_CELL_CELL_FUSION | 1.19e-04 | 13 | 18 | 2 | M46426 | |
| Pubmed | Comparison of TFII-I gene family members deleted in Williams-Beuren syndrome. | 6.71e-07 | 2 | 29 | 2 | 15388857 | |
| Pubmed | 2.01e-06 | 3 | 29 | 2 | 15100712 | ||
| Pubmed | 4.02e-06 | 4 | 29 | 2 | 21328569 | ||
| Pubmed | 4.02e-06 | 4 | 29 | 2 | 17823943 | ||
| Pubmed | 4.02e-06 | 4 | 29 | 2 | 23229069 | ||
| Pubmed | 4.02e-06 | 4 | 29 | 2 | 22899722 | ||
| Pubmed | Identification and characterization of TMEM16E and TMEM16F genes in silico. | 1.00e-05 | 6 | 29 | 2 | 15067359 | |
| Pubmed | ANOs 3-7 in the anoctamin/Tmem16 Cl- channel family are intracellular proteins. | 1.41e-05 | 7 | 29 | 2 | 22075693 | |
| Pubmed | 1.87e-05 | 8 | 29 | 2 | 22946059 | ||
| Pubmed | 1.87e-05 | 8 | 29 | 2 | 20056604 | ||
| Pubmed | Anoctamin/TMEM16 family members are Ca2+-activated Cl- channels. | 3.01e-05 | 10 | 29 | 2 | 19015192 | |
| Pubmed | Calcium-dependent phospholipid scramblase activity of TMEM16 protein family members. | 3.01e-05 | 10 | 29 | 2 | 23532839 | |
| Pubmed | N-terminal arginylation generates a bimodal degron that modulates autophagic proteolysis. | 3.01e-05 | 10 | 29 | 2 | 29507222 | |
| Pubmed | 3.01e-05 | 10 | 29 | 2 | 24692353 | ||
| Pubmed | Transcriptional fates of human-specific segmental duplications in brain. | 1.14e-04 | 19 | 29 | 2 | 30228200 | |
| Pubmed | TRAF4 promotes TGF-β receptor signaling and drives breast cancer metastasis. | 2.88e-04 | 30 | 29 | 2 | 23973329 | |
| Pubmed | The human cytoplasmic dynein interactome reveals novel activators of motility. | 6.39e-04 | 853 | 29 | 5 | 28718761 | |
| GeneFamily | Anoctamins | 4.68e-05 | 10 | 19 | 2 | 865 | |
| ToppCell | mild-B_intermediate|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 8.25e-06 | 200 | 29 | 4 | fe815824e9e4be3f3db73610e3814a7fd533da65 | |
| ToppCell | TCGA-Breast-Primary_Tumor-Breast_Carcinoma-Mucinous_Carcinoma-6|TCGA-Breast / Sample_Type by Project: Shred V9 | 7.97e-05 | 129 | 29 | 3 | b0c3cbab552e1d540e6b03a691dd245f81715e0b | |
| ToppCell | droplet-Heart-nan-18m-Hematologic-nan|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.56e-04 | 162 | 29 | 3 | 7f425a3983325a5a3ea33f812b15aa010cc55de0 | |
| ToppCell | 356C-Myeloid-Macrophage-SPP1+_Macrophage_4|Myeloid / Donor, Lineage, Cell class and subclass (all cells) | 1.68e-04 | 166 | 29 | 3 | 8d5d09f25e8903d481c2097fed435e69d42ccdb5 | |
| ToppCell | facs-Lung-24m-Hematologic-myeloid-classical_monocyte-classical_monocyte_l14|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 1.77e-04 | 169 | 29 | 3 | 813472d429c0b12580b17b440e00a6d8beb7947f | |
| ToppCell | PBMC-Severe-Lymphocyte-B-B_cell-B_memory-B_memory-6|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 1.96e-04 | 175 | 29 | 3 | eaec7fda07a9537d067ca13b607a8ab201caa7c4 | |
| ToppCell | facs-Marrow-B-cells-3m-Lymphocytic-early_pro_B_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.00e-04 | 176 | 29 | 3 | 29cda51a99100ddd2928cadc92da40f001d7e1f4 | |
| ToppCell | facs-Marrow-B-cells-3m-Lymphocytic-early_pro-B_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.00e-04 | 176 | 29 | 3 | 01774a86d7d92f31a056b753f9844f923038003e | |
| ToppCell | droplet-Lung-30m-Hematologic-myeloid-classical_monocyte-classical_monocyte_l2-17-52|30m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 2.10e-04 | 179 | 29 | 3 | af03705a783e77f75c44fdfa793cfdccbf9dd91c | |
| ToppCell | normal-na-Lymphocytic_B-B_mem-male|normal / PBMC cell types (v2) per disease, treatment status, and sex | 2.20e-04 | 182 | 29 | 3 | ee36ea6cb9a5a08aeb83f2b7a249255f0b1a9870 | |
| ToppCell | droplet-Marrow-nan-3m-Myeloid-promonocyte|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.20e-04 | 182 | 29 | 3 | bc8d621be57f76d718d9b0f11e023b0f4dcb668d | |
| ToppCell | Mild/Remission-B_intermediate-0|World / disease group and sub_cluster of B and Plasma cells(res = 0.5) | 2.42e-04 | 188 | 29 | 3 | 614032d18f8060bb12d1af7a1cf1cf4d8b2b505b | |
| ToppCell | renal_papilla_nuclei-Hypertensive_with+without-CKD-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Thick_Ascending_Limb_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 2.46e-04 | 189 | 29 | 3 | 8c8ca3b30d9be6c854615459a7bfba82b427c8bc | |
| ToppCell | CTRL-Lymphoid-B_cell|Lymphoid / Disease state, Lineage and Cell class | 2.46e-04 | 189 | 29 | 3 | 14f3a8c0f4f057ad4e6839b4c3eeaf956d6dc92e | |
| ToppCell | renal_papilla_nuclei-Hypertensive_with+without-CKD-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 2.46e-04 | 189 | 29 | 3 | 5d902a4660a27548764bf04c6de152b565da835c | |
| ToppCell | CF-Lymphoid-B_cell|CF / Disease state, Lineage and Cell class | 2.50e-04 | 190 | 29 | 3 | 374d8fd63c733178acab07682ed1519693efab45 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_B-B_cell-B_c03-CD27-AIM2|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.50e-04 | 190 | 29 | 3 | 0db545a4cba7534bad2693e0d565cde7dbc7a586 | |
| ToppCell | PBMC-Mild-Lymphocyte-B-B_cell-B_intermediate-B_intermediate-0|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 2.54e-04 | 191 | 29 | 3 | 5a9a592875fbd0b1429b48db29a760fdc9c2c856 | |
| ToppCell | PBMC-Severe-Lymphocyte-B-B_cell-B_intermediate-B_intermediate-0|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 2.54e-04 | 191 | 29 | 3 | b7d17d3ba488378b30f3732f8109f4a7c1673e61 | |
| ToppCell | systemic_lupus_erythematosus-treated-Lymphocytic_B-B_mem-female|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 2.58e-04 | 192 | 29 | 3 | 80a71ab3434076803466ccac0df73468889c7dd3 | |
| ToppCell | systemic_lupus_erythematosus-treated-Lymphocytic_B-B_mem|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 2.58e-04 | 192 | 29 | 3 | 75ce635d669ff77d1fd54e10467f21d5e5d67b08 | |
| ToppCell | moderate-Lymphoid-B_cell|Lymphoid / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls | 2.58e-04 | 192 | 29 | 3 | ae3727503c3b9f4695e565fd3161cc33b898f349 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_B-B_cell-B_c02-MS4A1-CD27|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.62e-04 | 193 | 29 | 3 | bbea475d2c4c7b29674ff302529f8f83dd666dcb | |
| ToppCell | PBMC-Mild-Lymphocyte-B-B_cell-B_intermediate|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 2.62e-04 | 193 | 29 | 3 | 7cc10e8b51091869d46e462f3214999e7b5348b1 | |
| ToppCell | PBMC_fresh-frozen-Mild-Moderate_convalescent_d36-51-Lymphocytic-Lymphocytic_B-B_cell-B_c02-MS4A1-CD27|Mild-Moderate_convalescent_d36-51 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.62e-04 | 193 | 29 | 3 | 749faa5c592ee354733f5a7363a4277ef3462b93 | |
| ToppCell | CF-Lymphoid|CF / Disease state, Lineage and Cell class | 2.62e-04 | 193 | 29 | 3 | 11de07d13a7da223990b56fa89ba7fc1c3dd0122 | |
| ToppCell | PBMC-Severe-Lymphocyte-B-B_cell-B_intermediate-|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 2.62e-04 | 193 | 29 | 3 | b5e44fe60dc84dc050d4fa3ccec4e257e51dc636 | |
| ToppCell | PBMC-Severe-Lymphocyte-B-B_cell-B_intermediate|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 2.62e-04 | 193 | 29 | 3 | e2cf2f4f142e1b4dda3ded28b5208eef3f301a43 | |
| ToppCell | PBMC-Mild-Lymphocyte-B-B_cell-B_intermediate|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09) | 2.66e-04 | 194 | 29 | 3 | 2b61023a602d336ed0de174e9141046173db34e6 | |
| ToppCell | COVID-19_Mild-Lymphoid_B-B_intermediate|COVID-19_Mild / Disease group, lineage and cell class | 2.66e-04 | 194 | 29 | 3 | bf6f72a489c62cbf1a679552d8c5eaaaa0b99d33 | |
| ToppCell | PBMC-Mild-Lymphocyte-B-B_cell-B_intermediate-|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 2.66e-04 | 194 | 29 | 3 | f2486b19ac52a48d19f80b38a5536bee3dad745b | |
| ToppCell | systemic_lupus_erythematosus-flare-Lymphocytic_B-B_mem-female|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 2.70e-04 | 195 | 29 | 3 | 51e6cfecd66a874673d0b79a295489a358bddfd5 | |
| ToppCell | systemic_lupus_erythematosus-flare-Lymphocytic_B-B_cell-female|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 2.70e-04 | 195 | 29 | 3 | 30eccfc08106627fae49b93094bbb40fd6888db2 | |
| ToppCell | PBMC_fresh-frozen-Mild-Moderate_progression_d12-25-Lymphocytic-Lymphocytic_B-B_cell|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.70e-04 | 195 | 29 | 3 | 481989d2e5bd2582da3d86b0155c4d6615317067 | |
| ToppCell | PBMC_fresh-frozen-Mild-Moderate_progression_d12-25-Lymphocytic-Lymphocytic_B|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.70e-04 | 195 | 29 | 3 | 6108a27523d1b93a7fbe35cb95704a5ad9071e3c | |
| ToppCell | systemic_lupus_erythematosus-flare-Lymphocytic_B-B_cell|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 2.70e-04 | 195 | 29 | 3 | e0b16ba18092e235d37c67f0762c80a5ec1714f8 | |
| ToppCell | mild_COVID-19-B_intermediate|mild_COVID-19 / disease group, cell group and cell class (v2) | 2.78e-04 | 197 | 29 | 3 | f669500120646f69355a6f920b892a6f2faeab63 | |
| ToppCell | mild_COVID-19-B_intermediate|World / disease group, cell group and cell class (v2) | 2.78e-04 | 197 | 29 | 3 | e909b898b7458071f176b6c04356ea3540589153 | |
| ToppCell | (5)_Dendritic_cell-(54)_pDC|(5)_Dendritic_cell / shred on Cell_type and subtype | 2.82e-04 | 198 | 29 | 3 | fc6c6b60dddd7f2f997af0f87fae33f1c23f34a8 | |
| ToppCell | Kidney-Leukocytes|Kidney / Skin and Kidney Cells in Lupus Nephritis Patients. | 2.82e-04 | 198 | 29 | 3 | 4050553f292ce00d547bc79207d6b9a44f4db34f | |
| ToppCell | control-B_intermediate|control / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 2.82e-04 | 198 | 29 | 3 | e24345c8cec8c21f7b5163b7326ba8f83a587ce3 | |
| ToppCell | mild-B_memory|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 2.86e-04 | 199 | 29 | 3 | e6ac9a0959b0de2c6a99298feb7715aa80ade1dd | |
| ToppCell | severe-B_memory|severe / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 2.86e-04 | 199 | 29 | 3 | 6d3436dd65d525aaa23ec02672005380f21c4d0f | |
| ToppCell | COVID-19-COVID-19_Mild-Lymphocyte-B-B_intermediate|COVID-19_Mild / Disease, condition lineage and cell class | 2.86e-04 | 199 | 29 | 3 | 1c6a08d01f6c1a2a4b6587d3a4522efbd03275e1 | |
| ToppCell | mild-B_memory|mild / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 2.86e-04 | 199 | 29 | 3 | 025bb65629d9e20c374e8f1ba08c36d1bb569190 | |
| ToppCell | COVID-19-COVID-19_Severe-Lymphocyte-B-B_intermediate|COVID-19_Severe / Disease, condition lineage and cell class | 2.86e-04 | 199 | 29 | 3 | ad3c369a67926725917b771094f82ca6dd2af783 | |
| ToppCell | mild-B_intermediate|mild / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 2.90e-04 | 200 | 29 | 3 | 8e3132a1fe3708f725c5c4077878fb87bbea3678 | |
| Disease | response to angiotensin-converting enzyme inhibitor | 2.49e-03 | 78 | 28 | 2 | EFO_0005325 | |
| Disease | susceptibility to scarlet fever measurement | 2.56e-03 | 79 | 28 | 2 | EFO_0008409 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| SCFYVAFFKGKFVGY | 571 | Q75V66 | |
| FSSHYKKFFCSYSEP | 311 | Q9Y6B7 | |
| CFYIAFFKGKFVGYP | 566 | Q4KMQ2 | |
| YVCFFGYPSFKYSHP | 36 | P11182 | |
| KFYCKPHYCYRLSGY | 811 | Q7RTP6 | |
| CYKHFYYFVKEFGLI | 186 | Q96BX8 | |
| TFDGKTYTFHGDCYY | 401 | Q02817 | |
| KYGYHISKTSYFLCY | 481 | Q6PCE3 | |
| KAFDRFFIHYPYCYG | 116 | Q86UA1 | |
| YSCHFKKGKRYFYFY | 76 | P48147 | |
| KHYGKYFEPEAYFPS | 171 | Q96NE9 | |
| VFPFHYKNGTYYDCI | 46 | Q075Z2 | |
| TCKVPGLYYFTYHAS | 161 | P02746 | |
| TTFFDYDYGAPCHKF | 21 | P41597 | |
| LSYYYMGFYIHSCPK | 401 | O95260 | |
| FFPPKSNKAYHYHSY | 636 | Q8IXB1 | |
| YKYLWGSYPKYKHHC | 891 | Q86UP8 | |
| YKYLWGSYPKYKHHC | 891 | Q6EKJ0 | |
| SKYSAGCIYYYPSFH | 881 | O95487 | |
| EAFKHLYFEKFPGYY | 521 | Q9H6R3 | |
| YTCNFLGCKKFYYSK | 801 | Q13129 | |
| HIYFKKFQYCGYAPH | 371 | Q9HBX9 | |
| ECFSPAFYTHKYGYK | 331 | Q9BUZ4 | |
| MFSFCHYYYFLPLKK | 151 | Q8IVQ6 | |
| YGCYAAKKYSYGHLP | 1856 | O43149 | |
| YHFKKGTEICNYSYS | 86 | Q5MNZ9 | |
| PYKCREYYKGFDHNS | 581 | Q9UL59 | |
| PKTHTGYKFYVCNEY | 256 | Q8WTR7 | |
| EYPCKFYHTGTKCYQ | 246 | Q8N5P1 |